D Schrag

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Influence of hospital procedure volume on outcomes following surgery for colon cancer
    D Schrag
    Department of Epidemiology and Biostatistics, Health Outcomes Research Group, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 284:3028-35. 2000
  2. ncbi Fragmentation of care for frequently hospitalized urban residents
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, and the Department of Health Policy, Mount Sinai School of Medicine, New York, New York 10021, USA
    Med Care 44:560-7. 2006
  3. ncbi Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 65:1118-25. 2005
  4. ncbi Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 98:163-71. 2006
  5. ncbi Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:233-7. 2007
  6. ncbi Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Surg Oncol 83:68-78; discussion 78-9. 2003
  7. ncbi Adherence to surveillance among patients with superficial bladder cancer
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 95:588-97. 2003
  8. pmc Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Department of Medicine, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 236:583-92. 2002
  9. ncbi Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Care 40:IV-96-103. 2002
  10. ncbi Cetuximab therapy and symptomatic hypomagnesemia
    Deborah Schrag
    Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
    J Natl Cancer Inst 97:1221-4. 2005

Research Grants

Detail Information

Publications84

  1. ncbi Influence of hospital procedure volume on outcomes following surgery for colon cancer
    D Schrag
    Department of Epidemiology and Biostatistics, Health Outcomes Research Group, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    JAMA 284:3028-35. 2000
    ..Conflicting evidence exists as to whether the association between hospital experience and favorable health outcomes also applies to more frequently performed operations, such as those for colon cancer...
  2. ncbi Fragmentation of care for frequently hospitalized urban residents
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, and the Department of Health Policy, Mount Sinai School of Medicine, New York, New York 10021, USA
    Med Care 44:560-7. 2006
    ..Fragmentation across sites of care may impede efficient healthcare delivery...
  3. ncbi Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 65:1118-25. 2005
    ..To describe the population-based patterns of care among patients with muscle-invasive bladder cancer...
  4. ncbi Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 98:163-71. 2006
    ..e., hospital or surgeon) procedure volumes and patient outcomes have been demonstrated for many types of cancer operation. We performed a population-based cohort study to examine these associations for ovarian cancer resections...
  5. ncbi Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:233-7. 2007
    ..As chemotherapy costs escalate, financial concerns have become relevant for more cancer patients. Yet, little is known about how oncologists communicate with patients about coping with chemotherapy treatment costs...
  6. ncbi Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Surg Oncol 83:68-78; discussion 78-9. 2003
    ..However, the importance of surgeon case volume as a determinant of outcome has been less well studied, and it is unclear whether hospital or surgeon volume is the more powerful predictor of outcomes...
  7. ncbi Adherence to surveillance among patients with superficial bladder cancer
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 95:588-97. 2003
    ..We examined the degree to which bladder cancer patients undergo the recommended surveillance procedures and identified patient and primary care provider characteristics associated with nonadherence to these recommendations...
  8. pmc Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Department of Medicine, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 236:583-92. 2002
    ..To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer...
  9. ncbi Identifying and measuring hospital characteristics using the SEER-Medicare data and other claims-based sources
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Care 40:IV-96-103. 2002
    ....
  10. ncbi Cetuximab therapy and symptomatic hypomagnesemia
    Deborah Schrag
    Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
    J Natl Cancer Inst 97:1221-4. 2005
    ..Because symptoms may be rapidly ameliorated with supplementation, we suggest that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary...
  11. ncbi Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare
    D Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:3712-8. 2001
    ..To examine the relationship between patient characteristics and the use of adjuvant pelvic radiation with and without chemotherapy among patients aged 65 years and older with stage II and III rectal cancer...
  12. ncbi Age and adjuvant chemotherapy use after surgery for stage III colon cancer
    D Schrag
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 93:850-7. 2001
    ..However, the extent to which adjuvant therapy is used outside the clinical trial setting, particularly among the elderly, is unknown...
  13. ncbi The influence of hospital volume on survival after resection for lung cancer
    P B Bach
    Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 345:181-8. 2001
    ....
  14. doi Physician visits prior to treatment for clinically localized prostate cancer
    Thomas L Jang
    Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York, USA
    Arch Intern Med 170:440-50. 2010
    ..We evaluated how visits to specialists and primary care physicians (PCPs) by men with localized prostate cancer are related to treatment choice...
  15. ncbi The effect of clustering of outcomes on the association of procedure volume and surgical outcomes
    Katherine S Panageas
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Intern Med 139:658-65. 2003
    ....
  16. doi Meeting the 12 lymph node (LN) benchmark in colon cancer
    A Rajput
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
    J Surg Oncol 102:3-9. 2010
    ..Examining >or=12 LN in colon cancer has been suggested as a quality metric. The purpose of this study was to determine whether the 12 LN benchmark is achieved at NCCN centers compared to a US population-based sample...
  17. ncbi The price tag on progress--chemotherapy for colorectal cancer
    Deborah Schrag
    Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 351:317-9. 2004
  18. ncbi Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer
    Deborah Schrag
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3999-4005. 2002
    ..Nevertheless, patients may receive this treatment despite its uncertain benefit. The objective of this study was to determine the extent to which adjuvant chemotherapy is used for patients with stage II colon cancer...
  19. doi Clinical and pathologic factors that predict lymph node yield from surgical specimens in colorectal cancer: a population-based study
    Joanne F Chou
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 116:2560-70. 2010
    ..However, heterogeneity in LN harvest exists. The objective of this study was to investigate the clinicopathologic factors that influence LN yield...
  20. ncbi Can differences in bowel function after surgery for rectal cancer be identified by the European Organization for Research and Treatment of Cancer quality of life instrument?
    Heather B Neuman
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, New York 10021, USA
    Ann Surg Oncol 14:1727-34. 2007
    ....
  21. doi Identification of patients with high-risk stage II colon cancer for adjuvant therapy
    Hak Mien Quah
    Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Dis Colon Rectum 51:503-7. 2008
    ..The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients...
  22. ncbi Squamous-cell carcinoma of the rectum: a rare but curable tumor
    Caio S R Nahas
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Dis Colon Rectum 50:1393-400. 2007
    ..This study was designed to evaluate one institution's experience with treatment outcomes for rectal squamous-cell carcinoma...
  23. doi Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Invest 27:402-6. 2009
    ..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
  24. doi Squamous-cell carcinoma of the anal canal: predictors of treatment outcome
    Ramin Roohipour
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 51:147-53. 2008
    ..The incidence of anal canal squamous-cell carcinoma is increasing. Limited data exist on predictors of treatment failure. This study was designed to identify predictors for relapse/persistence after first-line therapy...
  25. doi Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation
    Hak Mien Quah
    Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 113:57-64. 2008
    ....
  26. pmc Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer
    Justin E Bekelman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 69:1456-66. 2007
    ..S. men...
  27. ncbi Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer
    Justin E Bekelman
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 66:492-9. 2006
    ..Yet practice guidelines differ in their recommendations with regard to PORT use. We examine temporal trends in PORT use before and after the 1998 meta-analysis...
  28. ncbi The surgical learning curve for prostate cancer control after radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Natl Cancer Inst 99:1171-7. 2007
    ..We analyzed the surgical learning curve for prostate cancer recurrence after radical prostatectomy...
  29. pmc Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
    Ethan Basch
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Med Inform Assoc 14:264-8. 2007
    ..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
  30. ncbi Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 7:903-9. 2006
    ..We aimed to compare the reporting of symptom severity reported by patients and clinicians...
  31. ncbi Desire for information and involvement in treatment decisions: elderly cancer patients' preferences and their physicians' perceptions
    Elena B Elkin
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
    J Clin Oncol 25:5275-80. 2007
    ..Shared decision making is a tenet of contemporary medicine and oncology practice. How involved elderly patients want to be in making treatment decisions and how physicians perceive patient preferences for such involvement are uncertain...
  32. ncbi Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Stat Med 26:2017-35. 2007
    ..By contrast, the cluster weighted GEE method is inefficient...
  33. ncbi Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, and the Office of the Physician in Chief, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5374-80. 2007
    ..In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly...
  34. pmc Geographic access and the use of screening mammography
    Elena B Elkin
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Med Care 48:349-56. 2010
    ..Inadequate mammography resources in some areas may impair access to this technology. We assessed the relationship between availability of mammography machines and the use of screening...
  35. doi Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data
    Cami S Sima
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Appl Health Econ Health Policy 8:37-51. 2010
    ....
  36. pmc Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes
    Ethan Basch
    Health Outcomes Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, New York, NY 10065, USA
    J Natl Cancer Inst 101:1624-32. 2009
    ..Patient self-reporting has been proposed as an additional data source, but the implications of such a shift are not understood...
  37. pmc Nodal staging score: a tool to assess adequate staging of node-negative colon cancer
    Mithat Gonen
    Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, 1275 York Ave, Box 44, New York, NY 10065, USA
    J Clin Oncol 27:6166-71. 2009
    ..We sought to refine this definition by quantifying the likelihood that a pathologically node-negative patient has, indeed, no positive nodes...
  38. doi Factors associated with sphincter-preserving surgery for rectal cancer at national comprehensive cancer network centers
    Larissa K Temple
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 250:260-7. 2009
    ..To determine rate and predictors of sphincter-preserving surgery (SPS) for rectal cancer patients treated at specialty institutions...
  39. pmc Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
    ..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
  40. pmc Disenrollment from Medicare managed care among beneficiaries with and without a cancer diagnosis
    Elena B Elkin
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 44, New York, NY 10021, USA
    J Natl Cancer Inst 100:1013-21. 2008
    ..We compared rates of voluntary disenrollment from Medicare managed care to traditional fee-for-service Medicare among Medicare managed care enrollees with and without a cancer diagnosis...
  41. doi How to build and interpret a nomogram for cancer prognosis
    Alexia Iasonos
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, 3rd Floor, New York, NY 10021, USA
    J Clin Oncol 26:1364-70. 2008
    ..This guide provides a nonstatistical audience with a methodological approach for building, interpreting, and using nomograms to estimate cancer prognosis or other health outcomes...
  42. pmc Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 53:960-6. 2008
    ..We previously demonstrated that there is a learning curve for open radical prostatectomy. We sought to determine whether the effects of the learning curve are modified by pathologic stage...
  43. doi Individualized prediction of colon cancer recurrence using a nomogram
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:380-5. 2008
    ..Although easy to implement, there remains significant heterogeneity within each stage grouping. In the era of multimodality treatment, a more refined tool is needed to predict recurrence...
  44. pmc Cancer screening among patients with advanced cancer
    Camelia S Sima
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, Second Floor, New York, NY 10065, USA
    JAMA 304:1584-91. 2010
    ..Cancer screening has been integrated into routine primary care but does not benefit patients with limited life expectancy...
  45. ncbi Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort
    Elena B Elkin
    Health Outcomes Research Group and Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2757-64. 2006
    ..Our goal was to assess the relationship between adjuvant chemotherapy use and survival in a large, population-based cohort of older women with hormone receptor (HR) -negative breast cancer...
  46. ncbi Patient online self-reporting of toxicity symptoms during chemotherapy
    Ethan Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 E 63rd St, New York, NY 10021, USA
    J Clin Oncol 23:3552-61. 2005
    ..Currently, clinicians collect symptom information via complex and often inefficient mechanisms, but there is growing interest in collecting outcome information directly from patients...
  47. ncbi The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer
    Larissa K Temple
    Department of Surgery, Division of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Dis Colon Rectum 48:1353-65. 2005
    ..Therefore, the purpose of this study was to develop an instrument to evaluate bowel function after sphincter-preserving surgery...
  48. ncbi Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
    J Clin Oncol 23:1803-10. 2005
    ....
  49. ncbi Resurrecting treatment histories of dead patients: a study design that should be laid to rest
    Peter B Bach
    The Health Outcomes Research Group, The Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 292:2765-70. 2004
    ..We conclude that studying care received prior to death can lead to invalid conclusions about the quality or type of care provided to dying patients...
  50. ncbi Use of surgery among elderly patients with stage IV colorectal cancer
    Larissa K F Temple
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:3475-84. 2004
    ..The purpose of this study was to evaluate surgical practice patterns for patients > or = 65 years of age with stage IV CRC in a US population-based cohort...
  51. ncbi Primary care physicians who treat blacks and whites
    Peter B Bach
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 351:575-84. 2004
    ..Black patients may receive their care from a subgroup of physicians whose qualifications or resources are inferior to those of the physicians who treat white patients...
  52. ncbi Use of information resources by patients with cancer and their companions
    Ethan M Basch
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2476-83. 2004
    ..It is not clear as to whether patients and their companions differ in their patterns of content seeking...
  53. ncbi The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma
    Nabil P Rizk
    Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 198:42-50. 2004
    ..Strategies to optimize surgical technique have been less well studied. We sought to assess the relation between complications related to surgical technique and outcomes after esophagogastrectomy for cancer...
  54. ncbi Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations
    Peter B Bach
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Med Care 40:IV-19-25. 2002
    ..Finally, they describe the available data on date of death, and explain why confidence in these measures is justified...
  55. ncbi Variations in morbidity after radical prostatectomy
    Colin B Begg
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 346:1138-44. 2002
    ..Recent studies of surgery for cancer have demonstrated variations in outcomes among hospitals and among surgeons. We sought to examine variations in morbidity after radical prostatectomy for prostate cancer...
  56. ncbi The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999
    Elena B Elkin
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 104:1149-57. 2005
    ..The objective of the current study was to characterize within-stage migration of tumor size in breast carcinoma, and to estimate the effect of this shift on reported breast carcinoma survival...
  57. ncbi When you look matters: the effect of assessment schedule on progression-free survival
    Katherine S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd St, 3rd Fl, New York, NY 10021, USA
    J Natl Cancer Inst 99:428-32. 2007
    ..The decision to use PFS as a primary endpoint should be made carefully when designing clinical trials, and investigators focused on a particular disease should develop consensus standards and strive for consistent surveillance intervals...
  58. ncbi Young age influences treatment but not outcome of colon cancer
    H M Quah
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 14:2759-65. 2007
    ..The aim of this study was to determine the association between age, clinicopathologic features, adjuvant therapy, and outcomes following colon cancer resection...
  59. ncbi A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic
    Elizabeth Y Chiao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Acquir Immune Defic Syndr 40:451-5. 2005
    ..The incidence of SCCA has particularly increased among men and those between 30 and 54 years of age since the introduction of HAART...
  60. ncbi Missed opportunities: racial disparities in adjuvant breast cancer treatment
    Nina A Bickell
    Department of Health Policy, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Oncol 24:1357-62. 2006
    ..We sought to measure a racial disparity in the underuse of adjuvant treatments for early-stage breast cancer and to identify associated factors...
  61. doi Use of high technology imaging for surveillance of early stage breast cancer
    K S Panageas
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 307 East 63rd Street, 3rd Floor, New York, NY 10021, USA
    Breast Cancer Res Treat 131:663-70. 2012
    ..Strategies to foster judicious utilization of HTRI should be a priority...
  62. ncbi Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation
    P B Bach
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 98:3234-40. 2001
    ..The presence of this feature may justify the recommendation to withdraw life-sustaining measures...
  63. pmc Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer
    Andrea C Phelps
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    JAMA 301:1140-7. 2009
    ..Patients frequently rely on religious faith to cope with cancer, but little is known about the associations between religious coping and the use of intensive life-prolonging care at the end of life...
  64. ncbi Radiation therapy facilities in the United States
    Leslie K Ballas
    The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 66:1204-11. 2006
    ..Our goal was to construct a comprehensive database of all radiation therapy facilities in the United States that can be used for future health services research in radiation oncology...
  65. ncbi An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer
    Deborah Schrag
    Memorila Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:1799-802. 2005
  66. ncbi Survival of blacks and whites after a cancer diagnosis
    Peter B Bach
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    JAMA 287:2106-13. 2002
    ..Yet, few studies have evaluated whether lower-quality treatment and shorter overall life expectancy due to a greater burden of other illnesses may explain the survival discrepancy...
  67. doi Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer
    M J Gollub
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Eur Radiol 22:821-31. 2012
    ..To determine the ability of dynamic contrast enhanced (DCE-MRI) to predict pathological complete response (pCR) after preoperative chemotherapy for rectal cancer...
  68. ncbi Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 139:649-57. 2003
    ..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
  69. ncbi Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population
    Joan L Warren
    Applied Research Program, National Cancer Institute, Bethesda, Maryland 20892 7344, USA
    Med Care 40:IV-3-18. 2002
    ..The use of this database to study cancer screening, treatment, outcomes, and costs has grown in recent years...
  70. ncbi Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:166-74. 2004
    ..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
  71. ncbi Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients
    Craig C Earle
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 98:172-80. 2006
    ..e., better outcomes). We examined associations between physician specialty and outcomes in a population-based cohort of elderly ovarian cancer surgery patients...
  72. ncbi American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Al B Benson
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 22:3408-19. 2004
    ....
  73. ncbi American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays
    Deborah Schrag
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, Alexandria, VA 22314, USA
    J Clin Oncol 22:3631-8. 2004
    ..To develop a technology assessment of chemotherapy sensitivity and resistance assays in order to define the role of these tests in routine oncology practice...
  74. ncbi Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma
    Bruce E Hillner
    Department of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Cancer 104:1871-84. 2005
    ..The trade-offs between costs and survival for these two regimens have not been explored...
  75. ncbi Discussing drug costs with patients
    Deborah Schrag
    Clin Adv Hematol Oncol 3:525-6. 2005
  76. ncbi Using propensity scores to estimate the cost-effectiveness of medical therapies
    Alka Indurkhya
    Department of Society, Human Development and Health, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Stat Med 25:1561-76. 2006
    ..Our method is illustrated by applying it to SEER-Medicare data for muscle invasive bladder cancer to determine the most cost-effective treatment protocol...
  77. ncbi A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients
    Carrie N Klabunde
    Health Services and Economics Branch, Applied Research Program, National Cancer Institute, Bethesda, MD 20892 7344, USA
    Ann Epidemiol 17:584-90. 2007
    ....
  78. ncbi Potentially avoidable hospitalizations for COPD and pneumonia: the role of physician and practice characteristics
    Ann S O'Malley
    Center for Studying Health System Change, Washington, DC 20024 2512, USA
    Med Care 45:562-70. 2007
    ..Hospitalizations for bacterial pneumonia and chronic obstructive pulmonary disease (COPD) occur frequently, but many are potentially avoidable...
  79. ncbi Communication and coordination: the keys to quality
    Deborah Schrag
    J Clin Oncol 23:6452-5. 2005
  80. ncbi Care patterns in Medicare and their implications for pay for performance
    Hoangmai H Pham
    Center for Studying Health System Change, Washington, DC 20024, USA
    N Engl J Med 356:1130-9. 2007
    ....
  81. doi Enhancing cancer registry data to promote rational health system design
    Deborah Schrag
    J Natl Cancer Inst 100:378-9. 2008
  82. ncbi Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging
    Seung Yong Jeong
    J Natl Cancer Inst 97:1705-6; author reply 1706-7. 2005
  83. doi American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures
    Christopher E Desch
    National Comprehensive Cancer Network, Fort Washington, PA, USA
    J Clin Oncol 26:3631-7. 2008
    ..Representatives from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) collaborated to create metrics suitable for national performance measurement...
  84. ncbi Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment
    Brenda K Edwards
    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892 8315, USA
    J Natl Cancer Inst 97:1407-27. 2005
    ..This year's report updates statistics on the 15 most common cancers in the five major racial/ethnic populations in the United States for 1992-2002 and features population-based trends in cancer treatment...

Research Grants2

  1. GENETIC PREDISPOSITION TESTING IN COLORECTAL CANCER
    Deborah Schrag; Fiscal Year: 2002
    ..abstract_text> ..
  2. Validation of Medicare Claims to Define Chemotherapy Use
    Deborah Schrag; Fiscal Year: 2005
    ..This knowledge has the potential to lay the groundwork for development of an inexpensive and efficient system for monitoring and improving the quality of US cancer care. ..